Shares of this pharmaceutical company gained over 3 per cent after receiving approval from the USFDA

Stock closed after a strong surge of 3.59 per cent from its previous day's close.

The stock opened at Rs 725.55 and touched its day high at Rs 757.25 on BSE and closed on Wednesday at Rs 751.25 a piece.

Management informed that The American Food and Drug Administration (U.S. FDA) has approved Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, a generic version of Briviact® Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg from UCB Inc., according to the leading global pharmaceutical company Lupin Limited (Lupin). The item will be produced at Lupin's plant in Nagpur, India.

Lupin is regarded as one of the biggest producers of anti-tuberculosis medications in the world. The business holds a sizeable market share in numerous therapeutic areas, including cardiovascular (statins and prils), diabetes, asthma, paediatric, gastrointestinal (GI), anti-infective (AI), and non-steroidal anti-inflammatory drugs (NSAIDs). Additionally, the business has been proud to hold onto its global leadership positions in other therapy areas including anti-TB and cephalosporin over the years.

This BSE group “A” stock touched its 52-week High at Rs 971.30 whereas the 52-week low stood at Rs 583.05. Presently, the market cap of the company is Rs 34,163.89 crore. The promoters hold 47.11 per cent of the company, while Institutions and Non-Institutions have 41.44 per cent and 11.45 per cent, respectively.